Literature DB >> 28507797

IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid.

D Croxatto1, S Martini2, L Chiossone3, F Scordamaglia4, C F Simonassi4, L Moretta5, M C Mingari1,2, P Vacca1,2.   

Abstract

Natural Killer (NK) cells are capable of recognizing and killing cancer cells and play an important role in tumor immunosurveillance. However, tumor-infiltrating NK cells are frequently impaired in their functional capability. A remarkable exception is represented by NK cells isolated from malignant pleural effusions (PE) that are not anergic and, upon IL2-induced activation, efficiently kill tumor cells. Although IL2 is used in various clinical trials, severe side effects may occur in treated patients. In this study, we investigated whether also other clinical-grade cytokines could induce strong cytotoxicity in NK cells isolated from pleural fluid of patients with primary or metastatic tumors of different origins. We show that PE-NK cells, cultured for short-time intervals with IL15, maintain the CD56bright phenotype, a high expression of the main activating receptors, produce cytokines and kill tumor cells in vitro similarly to those treated with IL2. Moreover, IL15-activated PE-NK cells could greatly reduce the growth of established tumors in mice. This in vivo antitumor effect correlated with the ability of IL15-activated PE-NK cells to traffic from periphery to the tumor site. Finally, we show that IL15 can counteract the inhibitory effect of the tumor pleural microenvironment. Our study suggests that IL15-activated NK cells isolated from pleural fluid (otherwise discarded after thoracentesis) may represent a suitable source of effector cells to be used in adoptive immunotherapy of cancer.

Entities:  

Keywords:  Adoptive immunotherapy; IL15; NK cells; innate lymphoid cells (ILC); pleural fluid; pleural tumors

Year:  2017        PMID: 28507797      PMCID: PMC5414879          DOI: 10.1080/2162402X.2017.1293210

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  70 in total

1.  Cytokine-induced memory-like natural killer cells.

Authors:  Megan A Cooper; Julie M Elliott; Peter A Keyel; Liping Yang; Javier A Carrero; Wayne M Yokoyama
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-30       Impact factor: 11.205

Review 2.  Trial Watch-Immunostimulation with cytokines in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Norma Bloy; Aitziber Buqué; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

3.  Allogeneic natural killer cells for refractory lymphoma.

Authors:  Veronika Bachanova; Linda J Burns; David H McKenna; Julie Curtsinger; Angela Panoskaltsis-Mortari; Bruce R Lindgren; Sarah Cooley; Daniel Weisdorf; Jeffrey S Miller
Journal:  Cancer Immunol Immunother       Date:  2010-08-03       Impact factor: 6.968

4.  Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines.

Authors:  Niels Halama; Monika Braun; Christoph Kahlert; Anna Spille; Christian Quack; Nuh Rahbari; Moritz Koch; Jürgen Weitz; Matthias Kloor; Inka Zoernig; Peter Schirmacher; Karsten Brand; Niels Grabe; Christine S Falk
Journal:  Clin Cancer Res       Date:  2011-02-15       Impact factor: 12.531

5.  Interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells.

Authors:  L Rodella; L Zamai; R Rezzani; M Artico; G Peri; M Falconi; A Facchini; G Pelusi; M Vitale
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

6.  Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Authors:  Jeffrey W Leong; Julie M Chase; Rizwan Romee; Stephanie E Schneider; Ryan P Sullivan; Megan A Cooper; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-13       Impact factor: 5.742

7.  Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.

Authors:  François Ghiringhelli; Pierre E Puig; Stephan Roux; Arnaud Parcellier; Elise Schmitt; Eric Solary; Guido Kroemer; François Martin; Bruno Chauffert; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

Review 8.  Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells.

Authors:  Nicolas Dulphy; Anne-Sophie Chrétien; Zena Khaznadar; Cyril Fauriat; Arash Nanbakhsh; Anne Caignard; Salem Chouaib; Daniel Olive; Antoine Toubert
Journal:  Front Immunol       Date:  2016-03-09       Impact factor: 7.561

9.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.

Authors:  Cameron S Brandt; Myriam Baratin; Eugene C Yi; Jacob Kennedy; Zeren Gao; Brian Fox; Betty Haldeman; Craig D Ostrander; Tomonori Kaifu; Christian Chabannon; Alessandro Moretta; Robert West; Wenfeng Xu; Eric Vivier; Steven D Levin
Journal:  J Exp Med       Date:  2009-06-15       Impact factor: 14.307

10.  Subtypes of cytotoxic lymphocytes and natural killer cells infiltrating cancer nests correlate with prognosis in patients with vulvar squamous cell carcinoma.

Authors:  Jacek Jan Sznurkowski; Anton Zawrocki; Wojciech Biernat
Journal:  Cancer Immunol Immunother       Date:  2013-12-25       Impact factor: 6.968

View more
  6 in total

Review 1.  Making cold malignant pleural effusions hot: driving novel immunotherapies.

Authors:  Pranav Murthy; Chigozirim N Ekeke; Kira L Russell; Samuel C Butler; Yue Wang; James D Luketich; Adam C Soloff; Rajeev Dhupar; Michael T Lotze
Journal:  Oncoimmunology       Date:  2019-01-22       Impact factor: 8.110

2.  Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor.

Authors:  Nicola Tumino; Stefania Martini; Enrico Munari; Francesca Scordamaglia; Francesca Besi; Francesca Romana Mariotti; Giuseppe Bogina; Maria Cristina Mingari; Paola Vacca; Lorenzo Moretta
Journal:  Int J Cancer       Date:  2019-03-26       Impact factor: 7.396

Review 3.  Exploiting Human NK Cells in Tumor Therapy.

Authors:  Paola Vacca; Gabriella Pietra; Nicola Tumino; Enrico Munari; Maria Cristina Mingari; Lorenzo Moretta
Journal:  Front Immunol       Date:  2020-01-17       Impact factor: 7.561

4.  HMGB1 Promotes Myeloid Egress and Limits Lymphatic Clearance of Malignant Pleural Effusions.

Authors:  Adam C Soloff; Katherine E Jones; Amy A Powers; Pranav Murthy; Yue Wang; Kira L Russell; Miranda Byrne-Steele; Amanda W Lund; Jian-Min Yuan; Sara E Monaco; Jian Han; Rajeev Dhupar; Michael T Lotze
Journal:  Front Immunol       Date:  2020-09-04       Impact factor: 7.561

Review 5.  Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28.

Authors:  F R Mariotti; L Quatrini; E Munari; P Vacca; N Tumino; G Pietra; M C Mingari; L Moretta
Journal:  Br J Pharmacol       Date:  2020-05-18       Impact factor: 8.739

Review 6.  Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity.

Authors:  Nicola Tumino; Francesca Besi; Stefania Martini; Anna Laura Di Pace; Enrico Munari; Linda Quatrini; Andrea Pelosi; Piera Filomena Fiore; Giulia Fiscon; Paola Paci; Francesca Scordamaglia; Maria Grazia Covesnon; Giuseppe Bogina; Maria Cristina Mingari; Lorenzo Moretta; Paola Vacca
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.